BeyondSpring to Host Second Quarter Financial Results and Corporate Update Conference Call on September 10, 2021
Get Alerts BYSI Hot Sheet
Join SI Premium – FREE
NEW YORK, Sept. 07, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (“BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that management will host a conference call to report its financial results for the second quarter ended June 30, 2021 and provide an update on recent corporate events on Friday, September 10, 2021 at 8:00 AM Eastern Time. Details for the conference call are below:
Friday, September 10 @ 8:00 AM Eastern Time | |
Domestic: | 877-451-6152 |
International: | 201-389-0879 |
Conference ID: | 13722968 |
Webcast: | http://public.viavid.com/index.php?id=146495 |
An archived replay of the webcast will be available for 90 days on BeyondSpring’s website at www.beyondspringpharma.com under “Events & Presentations” in the Investors section.
About BeyondSpringHeadquartered in New York City, BeyondSpring is a global biopharmaceutical company focused on developing innovative cancer therapies to improve clinical outcomes for patients who have high unmet medical needs. BeyondSpring’s first-in-class lead asset plinabulin, is being developed as a “pipeline in a drug” in various cancer indications as direct anti-cancer agent and to prevent chemotherapy induced neutropenia (CIN). Plinabulin and G-CSF combination has filed for approval and has received Priority Review and breakthrough designation in the U.S. and China for the prevention of CIN with a PDUFA date of November 30, 2021 in the U.S. In DUBLIN-3 study, a global, randomized, active controlled Phase 3 study, plinabulin and docetaxel combination has met the primary endpoint of extending overall survival compared to docetaxel alone, in 2nd/3rd line NSCLC (EGFR wild type). Additionally, it is being broadly studied in combination with various immuno-oncology regimens that could boost the efficacy of PD-1 / PD-L1 antibodies in seven different cancers. In addition to plinabulin, BeyondSpring’s extensive pipeline includes three pre-clinical immuno-oncology assets and a subsidiary, SEED Therapeutics, which is leveraging a proprietary targeted protein degradation drug discovery platform.
Investor Contact:Ashley R. RobinsonLifeSci Advisors, LLC+1 617-430-7577[email protected]
Media Contact:Darren Opland, Ph.D.LifeSci Communications+1 646-627-8387[email protected]
Source: BeyondSpring, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Transaction in Own Shares
- Robotic Helpers Test New Technology on the Space Station
- Innovature BPO Earns 2 Silver Awards at the Stevie Awards for Sales & Customer Service
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Earnings, PDUFASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!